Relutrigine

Name: Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Pharmacodynamics
Published: 2026-09-14T15:39:06-04:00

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacodynamics

1 evidence topic · 2 sources

Preclinical pharmacology

“PRAX-562 also exhibited potent use-dependent block (31× preference to tonic block).” (opens the source at this quote in a new tab)
“PRAX-562 (10 mg/kg po) completely prevented evoked seizures without affecting sLMA” (opens the source at this quote in a new tab)